Novartis AG (NVSEF) stock
NVSEFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVS
$146.46+2.56 (+1.78%)
Close on Oct 19, 2026Market cap $279.46BP/E 20.5Yield –
Novartis total assets
Total assets on the balance sheet at the end of each period.
Novartis's total assets was $122.03B at Jun 30, 2026. For fiscal 2025 it was $110.95B, up 8.5% from the year before. The highest annual figure on record is $145.56B in fiscal 2018.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $110.95B | +8.5% |
| FY2024 | Dec 31, 2024 | $102.25B | +2.3% |
| FY2023 | Dec 31, 2023 | $99.95B | -14.9% |
| FY2022 | Dec 31, 2022 | $117.45B | -10.9% |
| FY2021 | Dec 31, 2021 | $131.80B | +3.1% |
| FY2020 | Dec 31, 2020 | $127.78B | +7.9% |
| FY2019 | Dec 31, 2019 | $118.37B | -18.7% |
| FY2018 | Dec 31, 2018 | $145.56B | +9.4% |
| FY2017 | Dec 31, 2017 | $133.08B | +2.3% |
| FY2016 | Dec 31, 2016 | $130.12B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $122.03B | +25.2% |
| Q4 FY2025 | Dec 31, 2025 | $110.95B | +11.0% |
| Q2 FY2025 | Jun 30, 2025 | $104.40B | -5.9% |
| Q4 FY2024 | Dec 31, 2024 | $102.25B | -12.9% |
| Q2 FY2024 | Jun 30, 2024 | $97.51B | -20.7% |
| Q4 FY2023 | Dec 31, 2023 | $99.95B | -24.2% |
| Q2 FY2023 | Jun 30, 2023 | $110.98B | -10.5% |
| Q4 FY2022 | Dec 31, 2022 | $117.45B | -8.1% |
| Q2 FY2022 | Jun 30, 2022 | $122.91B | -0.7% |
| Q4 FY2021 | Dec 31, 2021 | $131.80B | +11.3% |
| Q2 FY2021 | Jun 30, 2021 | $124.02B | +6.6% |
| Q4 FY2020 | Dec 31, 2020 | $127.78B | -12.2% |
| Q2 FY2020 | Jun 30, 2020 | $123.76B | -12.9% |
| Q4 FY2019 | Dec 31, 2019 | $118.37B | -11.1% |
| Q2 FY2019 | Jun 30, 2019 | $116.29B | -10.6% |
| Q4 FY2018 | Dec 31, 2018 | $145.56B | – |
| Q2 FY2018 | Jun 30, 2018 | $142.06B | – |
| Q4 FY2017 | Dec 31, 2017 | $133.08B | – |
| Q4 FY2016 | Dec 31, 2016 | $130.12B | – |
See a number that looks wrong?